Abstract
Endometrial cancer (EC) is the sixth most prevalent type of cancer among women. Kinases, enzymes mediating the transfer of adenosine triphosphate (ATP) in several signaling pathways, play a significant role in carcinogenesis and cancer cells’ survival and proliferation. Cyclin-dependent kinases (CDKs) are involved in EC pathogenesis; therefore, CDK inhibitors (CDKin) have a noteworthy therapeutic potential in this type of cancer, particularly in EC type 1. Natural compounds have been used for decades in the treatment of cancer serving as a source of anticancer bioactive molecules. Many phenolic and non-phenolic natural compounds covering flavonoids, stilbenoids, coumarins, biphenyl compounds, alkaloids, glycosides, terpenes, and terpenoids have shown moderate to high effectiveness against CDKin-mediated carcinogenic signaling pathways (PI3K, ERK1/2, Akt, ATM, mTOR, TP53). Pharmaceutical regimens based on two natural compounds, trabectedin and ixabepilone, have been investigated in humans showing short and midterm efficacy as second-line treatments in phase II clinical trials. The purpose of this review is twofold: the authors first provide an overview of the involvement of kinases and kinase inhibitors in the pathogenesis and treatment of EC and then discuss the existing evidence about natural products’ derived kinase inhibitors in the management of the disease and outline relevant future research.
Highlights
Kinases play a significant role in tumorigenesis, cancer cells’ survival, and proliferation
These results suggested that berberine certainly can halt cell cycle progression and trigger apoptosis via modulation of the phosphatidylinositol 3-kinase (PI3K)/ Akt signaling pathway in endometrial cancers (Kuo et al, 2015)
Phenolic and non-phenolic natural compounds (Figure 4) serve as sources of Cyclin-dependent kinases (CDK) inhibitors (CDKin), which can be applied in clinical practice
Summary
Kinases play a significant role in tumorigenesis, cancer cells’ survival, and proliferation. Kinases constitute 2% of the total human genome and the first group of enzymes that play a significant role in oncogenic evolution and are a potential drug target in cancer therapy (Schwartz and Murray, 2011). Natural Kinase Inhibitors for Endometrial Cancer in tyrosine kinases are found to occur in different oncogenic conditions. As CDKs play an important role in ontogenesis in endometrial cancer (EC), CDK inhibitors (CDKin) have a noteworthy therapeutic potential in EC (Sanchez-Martinez et al, 2015). Recent studies screening natural compounds as kinase inhibitors indicated particular natural compounds, mostly polyphenols, with a major potential to mitigate kinase mutation. The bioactive compounds directly bind with tyrosine kinases receptors and can regulate many cell signaling pathways by altering their phosphorylation nature
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
